Bone marrow-derived proangiogenic cells in pancreatic cancer

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue SUPPL.2, 2012, Pages 23-26

  Mizukami, Yusuke ^a,b,c  

^a Sapporo Higashi Tokushukai Hospital   (Japan)

^b ASAHIKAWA MEDICAL COLLEGE   (Japan)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Angiogenesis; Bone marrow derived cell; Hedgehog; Pancreatic cancer

Indexed keywords

BEVACIZUMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; MITOGEN ACTIVATED PROTEIN KINASE; RAS PROTEIN; SONIC HEDGEHOG PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BONE MARROW CELL; BONE MARROW DERIVED PROANGIOGENIC CELL; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CARCINOGENESIS; DISEASE COURSE; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MESENCHYMAL STEM CELL; MICROVASCULATURE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; TUMOR XENOGRAFT;

EID: 84856950543     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.07012.x     Document Type: Article

References (50)

1. Matsuno S, Egawa S, Fukuyama S etal. Pancreatic Cancer Registry in Japan: 20years of experience. Pancreas 2004; 28: 219-30.
2. Jemal A, Siegel R, Ward E etal. Cancer statistics, 2008. CA Cancer J. Clin. 2008; 58: 71-96.
3. Burris HA 3rd, Moore MJ, Andersen J etal. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997; 15: 2403-13.
4. Moore MJ, Goldstein D, Hamm J etal. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 2007; 25: 1960-6.
5. Rinehart J, Adjei AA, Lorusso PM etal. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 2004; 22: 4456-62.
6. Kalra MK, Maher MM, Mueller PR, Saini S. State-of-the-art imaging of pancreatic neoplasms. Br. J. Radiol. 2003; 76: 857-65.
7. Ueda T, Oda T, Kinoshita T etal. Neovascularization in pancreatic ductal adenocarcinoma: microvessel count analysis, comparison with non-cancerous regions and other types of carcinomas. Oncol. Rep. 2002; 9: 239-45.
8. Niedergethmann M, Hildenbrand R, Wostbrock B etal. High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas. Pancreas 2002; 25: 122-9.
9. Yoshitomi H, Kobayashi S, Ohtsuka M etal. Specific expression of endoglin (CD105) in endothelial cells of intratumoral blood and lymphatic vessels in pancreatic cancer. Pancreas 2008; 37:275-81.
10. Kindler HL, Niedzwiecki D, Hollis D etal. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 2010; 28: 3617-22.
11. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009; 15: 232-9.
12. Paez-Ribes M, Allen E, Hudock J etal. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009; 15: 220-31.
13. Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br. J. Cancer 2007; 96: 1788-95.
14. Mizukami Y, Jo WS, Duerr EM etal. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat. Med. 2005; 11: 992-7.
15. Mizukami Y, Fujiki K, Duerr EM etal. Hypoxic regulation of vascular endothelial growth factor through the induction of phosphatidylinositol 3-Kinase/Rho/ROCK and c-Myc. J. Biol. Chem. 2006; 281: 13957-63.
16. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure: an obstacle in cancer therapy. Nat. Rev. Cancer 2004; 4: 806-13.
17. Apte MV, Park S, Phillips PA etal. Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas 2004; 29: 179-87.
18. Joyce JA, Pollard JW. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009; 9: 239-52.
19. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur. J. Cancer 2006; 42: 717-27.
20. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 2006; 6: 24-37.
21. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007; 67: 9518-27.
22. Tan MC, Goedegebuure PS, Belt BA etal. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J. Immunol. 2009; 182: 1746-55.
23. Omary MB, Lugea A, Lowe AW, Pandol SJ. The pancreatic stellate cell: a star on the rise in pancreatic diseases. J. Clin. Invest. 2007; 117: 50-9.
24. Russo FP, Alison MR, Bigger BW etal. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 2006; 130: 1807-21.
25. Ishii G, Sangai T, Oda T etal. Bone-marrow-derived myofibroblasts contribute to the cancer-induced stromal reaction. Biochem. Biophys. Res. Commun. 2003; 309: 232-40.
26. Kerbel RS. Tumor angiogenesis. N. Engl. J. Med. 2008; 358: 2039-49.
27. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008; 319: 195-8.
28. Quante M, Tu SP, Tomita H etal. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011; 19: 257-72.
29. Nagahama Y, Ueno M, Miyamoto S etal. PSF1, a DNA replication factor expressed widely in stem and progenitor cells, drives tumorigenic and metastatic properties. Cancer Res. 2010; 70: 1215-24.
30. Butler JM, Kobayashi H, Rafii S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. Nat. Rev. Cancer 2010; 10: 138-46.
31. Duda DG, Jain RK. Premetastatic lung "niche": is vascular endothelial growth factor receptor 1 activation required? Cancer Res. 2010; 70: 5670-3.
32. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
33. Shojaei F, Wu X, Zhong C etal. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007; 450: 825-31.
34. McAllister SS, Gifford AM, Greiner AL etal. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell 2008; 133: 994-1005.
35. Elkabets M, Gifford AM, Scheel C etal. Human tumors instigate granulin-expressing hematopoietic cells that promote malignancy by activating stromal fibroblasts in mice. J. Clin. Invest. 2011; 121: 784-99.
36. Thayer SP, di Magliano MP, Heiser PW etal. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 2003; 425: 851-6.
37. Ohuchida K, Mizumoto K, Fujita H etal. Sonic hedgehog is an early developmental marker of intraductal papillary mucinous neoplasms: clinical implications of mRNA levels in pancreatic juice. J. Pathol. 2006; 210: 42-8.
38. Yauch RL, Gould SE, Scales SJ etal. A paracrine requirement for hedgehog signalling in cancer. Nature 2008; 455: 406-10.
39. Nolan-Stevaux O, Lau J, Truitt ML etal. GLI1 is regulated through Smoothened-independent mechanisms in neoplastic pancreatic ducts and mediates PDAC cell survival and transformation. Genes Dev. 2009; 23: 24-36.
40. Bailey JM, Swanson BJ, Hamada T etal. Sonic hedgehog promotes desmoplasia in pancreatic cancer. Clin. Cancer Res. 2008; 14: 5995-6004.
41. Walter K, Omura N, Hong SM etal. Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts. Clin. Cancer Res. 2010; 16: 1781-9.
42. Lin N, Tang Z, Deng M etal. Hedgehog-mediated paracrine interaction between hepatic stellate cells and marrow-derived mesenchymal stem cells. Biochem. Biophys. Res. Commun. 2008; 372: 260-5.
43. Fontaine C, Cousin W, Plaisant M, Dani C, Peraldi P. Hedgehog signaling alters adipocyte maturation of human mesenchymal stem cells. Stem Cells 2008; 26: 1037-46.
44. Rowitch DH, S-Jacques B, Lee SM, Flax JD, Snyder EY, McMahon AP. Sonic hedgehog regulates proliferation and inhibits differentiation of CNS precursor cells. J. Neurosci. 1999; 19: 8954-65.
45. Pepicelli CV, Lewis PM, McMahon AP. Sonic hedgehog regulates branching morphogenesis in the mammalian lung. Curr. Biol. 1998; 8: 1083-6.
46. Pola R, Ling LE, Silver M etal. The morphogen Sonic hedgehog is an indirect angiogenic agent upregulating two families of angiogenic growth factors. Nat. Med. 2001; 7: 706-11.
47. Yamazaki M, Nakamura K, Mizukami Y etal. Sonic hedgehog derived from human pancreatic cancer cells augments angiogenic function of endothelial progenitor cells. Cancer Sci. 2008; 99: 1131-8.
48. Nakamura K, Sasajima J, Mizukami Y etal. Hedgehog promotes neovascularization in pancreatic cancers by regulating Ang-1 and IGF-1 expression in bone-marrow derived pro-angiogenic cells. PLoS ONE 2010; 5: e8824.
49. Guimaraes AR, Rakhlin E, Weissleder R, Thayer SP. Magnetic resonance imaging monitors physiological changes with antihedgehog therapy in pancreatic adenocarcinoma xenograft model. Pancreas 2008; 37: 440-4.
50. Feldmann G, Habbe N, Dhara S etal. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008; 57: 1420-30.